Oncology Institute (TOI) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Oncology Institute Revenue Highlights


Latest Revenue (Y)

$324.24M

Latest Revenue (Q)

$94.67M

Main Segment (Y)

Health Care, Patient Service

Oncology Institute Revenue by Period


Oncology Institute Revenue by Year

DateRevenueChange
2023-12-31$324.24M28.42%
2022-12-31$252.48M24.37%
2021-12-31$203.00M8.26%
2020-12-31$187.51M20.66%
2019-12-31$155.41M37.33%
2018-12-31$113.16M-

Oncology Institute generated $324.24M in revenue during NA 2023, up 28.42% compared to the previous quarter, and up 286.53% compared to the same period a year ago.

Oncology Institute Revenue by Quarter

DateRevenueChange
2024-03-31$94.67M10.35%
2023-12-31$85.79M4.57%
2023-09-30$82.03M2.26%
2023-06-30$80.22M5.29%
2023-03-31$76.19M6.68%
2022-12-31$71.42M9.92%
2022-09-30$64.98M6.66%
2022-06-30$60.92M10.44%
2022-03-31$55.16M5.46%
2021-12-31$52.30M0.06%
2021-09-30$52.27M4.88%
2021-06-30$49.84M2.60%
2021-03-31$48.58M-74.09%
2020-12-31$187.51M296.86%
2020-09-30$47.25M-0.06%
2020-06-30$47.28M7.40%
2020-03-31$44.02M17.83%
2018-12-31$37.36M-

Oncology Institute generated $94.67M in revenue during Q1 2024, up 10.35% compared to the previous quarter, and up 132.54% compared to the same period a year ago.

Oncology Institute Revenue Breakdown


Oncology Institute Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
Health Care, Patient Service$213.50M$166.78M$124.07M
Capitated Revenue$70.37M$61.34M$54.28M
Clinical Research Trials And Other Revenue$6.90M$6.36M$6.38M
Dispensary Revenue$103.83M$79.34M$72.55M
Fee For Service$143.13M$105.44M$69.79M

Oncology Institute's latest annual revenue breakdown by segment (product or service), as of Dec 23: Health Care, Patient Service (39.70%), Fee For Service (26.62%), Dispensary Revenue (19.31%), Capitated Revenue (13.09%), and Clinical Research Trials And Other Revenue (1.28%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22
Fee For Service$34.79M$72.79M$36.64M$33.70M$31.47M$28.27M$25.16M$20.54M
Dispensary Revenue$39.68M$54.40M$25.20M$24.24M$21.61M$18.84M$20.22M$18.68M
Clinical Research Trials And Other Revenue$2.53M$3.62M$1.60M$1.68M$1.82M$1.51M$1.59M$1.43M
Capitated Revenue$17.67M$37.02M$16.79M$16.57M$16.53M$16.36M$13.94M$14.52M
Health Care, Patient Service$52.45M$109.81M$53.43M$50.27M$47.99M$44.63M$39.11M$35.06M

Oncology Institute's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Health Care, Patient Service (35.65%), Dispensary Revenue (26.97%), Fee For Service (23.64%), Capitated Revenue (12.01%), and Clinical Research Trials And Other Revenue (1.72%).

Oncology Institute Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
UHSUniversal Health Services$14.28B$3.91B
SEMSelect Medical$6.66B$1.76B
EHCEncompass Health$4.80B$1.35B
AGLagilon health$4.32B$1.48B
ENSGEnsign Group$3.73B$1.08B
BKDBrookdale Senior Living$3.02B$777.54M
SGRYSurgery Partners$2.74B$762.10M
CANOCano Health$2.74B$788.07M
MDPediatrix Medical Group$1.99B$511.16M
ADUSAddus HomeCare$1.06B$286.92M
LFSTLifeStance Health Group$1.06B$300.44M
PNTGPennant Group$544.89M$156.91M
CCMConcord Medical Services$537.40M$34.94M
TOIOncology Institute$324.24M$94.67M
SNDASonida Senior Living$255.32M$70.21M
JYNTJoint$117.70M$30.26M

TOI Revenue FAQ


Oncology Institute's yearly revenue for 2023 was $324.24M, representing an increase of 28.42% compared to 2022. The company's yearly revenue for 2022 was $252.48M, representing an increase of 24.37% compared to 2021. TOI's yearly revenue for 2021 was $203M, representing an increase of 8.26% compared to 2020.

Oncology Institute's quarterly revenue for Q1 2024 was $94.67M, a 10.35% increase from the previous quarter (Q4 2023), and a 24.25% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $85.79M, a 4.57% increase from the previous quarter (Q3 2023), and a 20.11% increase year-over-year (Q4 2022). TOI's quarterly revenue for Q3 2023 was $82.04M, a 2.26% increase from the previous quarter (Q2 2023), and a 26.25% increase year-over-year (Q3 2022).

Oncology Institute's revenue growth rate for the last 3 years (2021-2023) was 59.72%, and for the last 5 years (2019-2023) was 108.64%.

Oncology Institute's revenue streams in c 23 are Health Care, Patient Service, Capitated Revenue, Clinical Research Trials And Other Revenue, Dispensary Revenue, and Fee For Service. Health Care, Patient Service generated $213.5M in revenue, accounting 39.70% of the company's total revenue, up 28.01% year-over-year. Capitated Revenue generated $70.37M in revenue, accounting 13.09% of the company's total revenue, up 14.72% year-over-year. Clinical Research Trials And Other Revenue generated $6.9M in revenue, accounting 1.28% of the company's total revenue, up 8.58% year-over-year. Dispensary Revenue generated $103.84M in revenue, accounting 19.31% of the company's total revenue, up 30.87% year-over-year. Fee For Service generated $143.13M in revenue, accounting 26.62% of the company's total revenue, up 35.74% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Oncology Institute was Health Care, Patient Service. This segment made a revenue of $213.5M, representing 39.70% of the company's total revenue.